Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nielsen, R, Wiggers, H, Halbirk, M, Bøtker, HE, Holst, JJ, Schmitz, O, Frandsen, E, Nielsen, S, Møller, N & Nørrelund, H 2012, 'Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients' Experimental and Clinical Endocrinology and Diabetes, vol. 120, no. 5, pp. 266-72. https://doi.org/10.1055/s-0032-1304605

APA

Nielsen, R., Wiggers, H., Halbirk, M., Bøtker, H. E., Holst, J. J., Schmitz, O., ... Nørrelund, H. (2012). Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients. Experimental and Clinical Endocrinology and Diabetes, 120(5), 266-72. https://doi.org/10.1055/s-0032-1304605

CBE

MLA

Vancouver

Author

Nielsen, R ; Wiggers, Henrik ; Halbirk, Mads ; Bøtker, Hans Erik ; Holst, Jens Juul ; Schmitz, Ole ; Frandsen, E ; Nielsen, S ; Møller, N ; Nørrelund, Helene. / Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients. In: Experimental and Clinical Endocrinology and Diabetes. 2012 ; Vol. 120, No. 5. pp. 266-72.

Bibtex

@article{f30a7cd9ac1b4d14a2088d6841b57b74,
title = "Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients",
abstract = "We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28{\%}±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.",
keywords = "Blood Glucose, Calorimetry, Indirect, Cross-Over Studies, Double-Blind Method, Drug Administration Schedule, Fatty Acids, Nonesterified, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Glucose Tolerance Test, Heart Failure, Humans, Insulin, Insulin Resistance, Male, Middle Aged",
author = "R Nielsen and Henrik Wiggers and Mads Halbirk and B{\o}tker, {Hans Erik} and Holst, {Jens Juul} and Ole Schmitz and E Frandsen and S Nielsen and N M{\o}ller and Helene N{\o}rrelund",
note = "{\circledC} J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.",
year = "2012",
doi = "10.1055/s-0032-1304605",
language = "English",
volume = "120",
pages = "266--72",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Johann Ambrosius Barth Verlag in Medizinverlage Heidelberg GmbH & Co. KG",
number = "5",

}

RIS

TY - JOUR

T1 - Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

AU - Nielsen, R

AU - Wiggers, Henrik

AU - Halbirk, Mads

AU - Bøtker, Hans Erik

AU - Holst, Jens Juul

AU - Schmitz, Ole

AU - Frandsen, E

AU - Nielsen, S

AU - Møller, N

AU - Nørrelund, Helene

N1 - © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

PY - 2012

Y1 - 2012

N2 - We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

AB - We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

KW - Blood Glucose

KW - Calorimetry, Indirect

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Fatty Acids, Nonesterified

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose Clamp Technique

KW - Glucose Tolerance Test

KW - Heart Failure

KW - Humans

KW - Insulin

KW - Insulin Resistance

KW - Male

KW - Middle Aged

U2 - 10.1055/s-0032-1304605

DO - 10.1055/s-0032-1304605

M3 - Journal article

VL - 120

SP - 266

EP - 272

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 5

ER -

ID: 36833023